Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus SOX versus SOX alone as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400091812Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of envafolimab, tegafur + gimeracil + oteracil and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Pathologic complete response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
envafolimabtegafur + gimeracil + oteraciloxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400091812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091812.